Major Depressive Disorder Clinical Trial
Official title:
Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder
This study investigates influences of nordadrenergic activity on cognition in patients with major depression regarding influences of early life stress.
Stress plays a major role in the development and maintenance of major depression disorder.
Indeed, various studies demonstrated maladaptive changes in physiological stress regulation
systems of depressive patients, i.e. in the hypothalamus-pituitary-adrenal axis and the locus
coeruleus-noradrenergic system. On a central level, changes of the locus
coeruleus-noradrenergic system have been demonstrated.This seems to be the case especially in
depressive patients with early life traumata. Comparable to the
hypothalamus-pituitary-adrenal axis, the locus coeruleus-noradrenergic system influences not
only the physiological stress response, but has also central influence with effects on
cognitive functions. Indeed, noradrenergic effects on cognitive functions such as attention,
learning and memory have been demonstrated in healthy individuals. Even though deficits in
cognitive domains are core symptoms of major depression, the relationship of the
noradrenergic system and cognitive processes has rarely been investigated so far.
In this project, the investigators will examine noradrenergic influences via administration
of the alpha2-receptor blocker yohimbine on cognitive and emotionally relevant processes in
depressive patients and controls. Additionally, the investigators will examine the influence
of early life traumata on these relationships. Thus, the investigators will examine
participants with and without major depression and with and without early life stress.
Results of this study will improve the understanding of cognitive dysfunctions associated
with the noradrenergic system in patients with major depression.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |